低剂量芦可替尼预防单倍体造血干细胞移植后移植物抗宿主病:多中心、开放标签、随机、对照、3期试验
该多中心开放标签随机对照3期试验纳入215例接受首次清髓性单倍体造血干细胞移植的血液恶性肿瘤患者,比较以低剂量芦可替尼替代吗替麦考酚酯的预防方案与标准预防方案。
要点
- 低剂量芦可替尼替代吗替麦考酚酯可显著降低单倍体移植后第100天II-IV级急性GVHD发生率。
- 芦可替尼组3-4级不良事件以血小板减少、中性粒细胞减少和贫血为主,毒性总体可控。
- 该方案支持进一步评估靶向JAK1/2抑制作为GVHD预防策略的组成部分。
核心结论
- 在抗胸腺细胞球蛋白、钙调磷酸酶抑制剂和短程甲氨蝶呤基础上,以低剂量芦可替尼替代吗替麦考酚酯可降低单倍体移植后第100天II-IV级急性GVHD,且毒性可控。
研究设计与样本
- 多中心、开放标签、随机、对照、3期试验,在中国五个中心开展,纳入12-70岁接受首次清髓性单倍体造血干细胞移植的血液恶性肿瘤患者。
- 患者随机1:1接受低剂量芦可替尼预防方案或标准预防方案,按中心和年龄(<40岁 vs ≥40岁)分层,采用计算机生成随机区组。
主要发现
- 共215例患者随机分组,206例纳入改良意向治疗分析(芦可替尼组103例,标准组103例)。
- 芦可替尼组最常见3-4级不良事件为血小板减少(17例 [17%])、中性粒细胞减少(14例 [14%])、贫血(12例 [12%])和膀胱炎(7例 [7%])。
- 芦可替尼组严重不良事件发生31例(30%),标准组36例(35%);芦可替尼组无致命性不良事件,标准组发生3例死亡。
关键数值与推荐
- 芦可替尼用法:体重≥50 kg者第1天起口服5 mg每日两次,体重<50 kg者5 mg每日一次,持续至第60天,无II-IV级急性GVHD者逐渐减量至第90天。
- 主要终点为第100天II-IV级急性GVHD累积发生率。
临床怎么用
- 对于接受单倍体造血干细胞移植且适合清髓性预处理的患者,可考虑在抗胸腺细胞球蛋白、钙调磷酸酶抑制剂和短程甲氨蝶呤基础上以低剂量芦可替尼替代吗替麦考酚酯进行GVHD预防。
- 需关注芦可替尼相关血液学毒性(血小板减少、中性粒细胞减少、贫血)及膀胱炎,并进行相应监测。
局限性
- 本研究为开放标签设计,未设盲法。
- 研究仅在中国五个中心开展,所有参与者均为中国人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after haploidentical haematopoietic stem-cell transplantation (HSCT). Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor with established activity in steroid-refractory GVHD, has shown promise for prophylaxis in early studies, but there is little evidence from randomised trials in the haploidentical HSCT setting. We investigated whether, within a backbone of antithymocyte globulin, calcineurin inhibitor, and short-course methotrexate, replacing mycophenolate mofetil with low-dose ruxolitinib could reduce acute GVHD after haploidentical HSCT. METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial conducted at five centres in China, eligible patients were aged 12-70 years, had haematological malignancies for which allogeneic HSCT was indicated, had a Karnofsky performance status of at least 70 or a Lansky score of at least 70 for patients younger than 16 years, and were undergoing their first myeloablative haploidentical HSCT. Patients were randomly assigned (1:1) to receive antithymocyte globulin, a calcineurin inhibitor, short-course methotrexate, and low-dose ruxolitinib, or standard prophylaxis with antithymocyte globulin, a calcineurin inhibitor, short-course methotrexate, and mycophenolate mofetil. Randomisation was stratified by centre and patient age (<40 years vs ≥40 years) using computer-generated permuted blocks with random block sizes. Oral ruxolitinib was started on day 1 at 5 mg twice daily for patients weighing at least 50 kg and 5 mg once daily for those weighing less than 50 kg, continued up to day 60, and then tapered to day 90 in the absence of grade II-IV acute GVHD. The primary endpoint was the cumulative incidence of grade II-IV acute GVHD by day 100. Efficacy and safety were analysed in the modified intention-to-treat population, which included all randomly assigned patients who received at least one dose of the assigned prophylaxis, excluding those with major protocol deviations. This trial is registered with ClinicalTrials.gov, NCT04838704, and is complete. FINDINGS: Between April 1, 2021, and Dec 28, 2023, 215 patients were randomly assigned, of whom 206 were included in the modified intention-to-treat population (103 in the ruxolitinib prophylaxis group and 103 in the standard prophylaxis group). The median recipient age was 40 years (IQR 24-48), 98 (48%) patients were female and 108 (52%) were male, and all participants were Chinese. Among surviving patients, the median follow-up was 26·4 months (IQR 20·0-33·3). By day 100, grade II-IV acute GVHD occurred in seven (cumulative incidence of 6·8% [95% CI 1·9-11·7]) of 103 patients in the ruxolitinib prophylaxis group and 38 (36·9% [27·5-46·3]) of 103 patients in the standard prophylaxis group (subdistribution hazard ratio 0·15, 95% CI 0·07-0·34; p<0·0001). The most common grade 3-4 adverse events in the ruxolitinib prophylaxis group and the standard prophylaxis group were thrombocytopenia (17 [17%] vs 11 [11%]), neutropenia (14 [14%] vs 9 [9%]), anaemia (12 [12%] vs 9 [9%]), and cystitis (7 [7%] vs 10 [10%]). Serious adverse events occurred in 31 (30%) patients in the ruxolitinib prophylaxis group and 36 (35%) patients in the standard prophylaxis group. No fatal adverse events occurred in the ruxolitinib prophylaxis group. Three deaths occurred in the standard prophylaxis group: pulmonary infection (n=1), sepsis, bacteraemia, or fungaemia (n=1) and transplant-associated thrombotic microangiopathy (n=1). No deaths were considered related to the assigned study drug. INTERPRETATION: Low-dose ruxolitinib, used in place of mycophenolate mofetil within a backbone of prophylactic antithymocyte globulin, calcineurin inhibitor, and short-course methotrexate, reduced grade II-IV acute GVHD by day 100 after haploidentical HSCT and had manageable toxicity. These findings support further evaluation of targeted JAK1/2 inhibition as part of GVHD prophylaxis. FUNDING: National Natural Science Foundation of China.
引用
- Wu H, Shi W, Shi Z, et al. Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2026. PMID: 42532067. doi:10.1016/S2352-3026(26)00167-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。